-
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study
Thursday, July 22, 2021 - 7:22am | 261Read More...Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did not meet its primary endpoint of improving clinical remission rates compared to...
-
Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients
Thursday, July 15, 2021 - 5:45am | 299Read More...Galapagos NV (NASDAQ: GLPG) reports topline results from three studies evaluating GLPG3970, a SIK inhibitor, in psoriasis, ulcerative colitis (UC), and rheumatoid arthritis (RA). 26-patient CALOSOMA psoriasis trial. At Week 6, four out of 13 patients on GLPG3970 had at least...
-
Johnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative Colitis
Friday, July 9, 2021 - 12:49pm | 199Read More...The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced new three-year data from the long-term extension (LTE) of the Stelara (ustekinumab) Phase 3 UNIFI study. Investigators designed the trial to evaluate the safety and efficacy of...
-
Eli Lilly's Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year
Friday, July 9, 2021 - 10:45am | 245Read More...Eli Lilly And Co (NYSE: LLY) has announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year. In a previously published Phase 2 study,...
-
Bristol-Myers' Zeposia Scores FDA Approval For Ulcerative Colitis
Friday, May 28, 2021 - 8:24am | 222Read More...The FDA has approved Bristol Myers Squibb & Co's (NYSE: BMY) Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD). A European marketing application for Zeposia for...
-
Progenity's Targeted Delivery Of Adalimumab Shows Encouraging Action In Animal Models Induced With Colitis
Wednesday, May 26, 2021 - 9:08am | 272Read More...Progenity Inc (NASDAQ: PROG) has announced results from a preclinical study evaluating the delivery of PGN-001 (adalimumab liquid formulation) drug substance directly to the colon in an animal model of induced colitis. Adalimumab is the active ingredient used in AbbVie Inc'...
-
Bristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate Zeposia
Monday, May 24, 2021 - 9:16am | 251Read More...Bristol-Myers Squibb & Co (NYSE: BMY) released positive new data on its ulcerative colitis (UC) candidate Zeposia (ozanimod) at Digestive Disease Week (DDW), highlighting the drug's clinical benefits and safety profile. According to one study, induction therapy with...
-
Eli Lilly Abandons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications
Tuesday, April 27, 2021 - 2:34pm | 494Read More...Tucked in its Q1 earnings release, Eli Lilly And Co (NYSE: LLY) has scrapped its plans to seek approval for mirikizumab in psoriasis. The company decided not to enter the market despite the anti-IL-23p19 antibody outperforming Novartis AG’s (NYSE: NVS)...
-
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
Monday, April 26, 2021 - 9:58am | 345Read More...I-Mab (NASDAQ: IMAB) has announced topline results from its Phase 2 study evaluating olamkicept (also known as TJ301) in patients with active ulcerative colitis (UC). The study met its primary endpoint and provided early evidence that I-Mab’s IL-6 inhibitor...
-
Eli Lilly's Mirikizumab Beat Placebo At Controlling, Resolving Ulcerative Colitis Symptoms
Tuesday, March 16, 2021 - 12:27pm | 223Read More...Eli Lilly and Co's (NYSE: LLY) Mirikizumab is now one step closer to get approval after announcing positive data from Phase 3 LUCENT-1 study in moderate to severe ulcerative colitis. The study met the primary endpoint of clinical remission at Week 12 compared to placebo when the...
-
AbbVie's Humira Gets FDA Approval For Pediatric Ulcerative Colitis
Thursday, February 25, 2021 - 8:12am | 183Read More...The FDA has approved AbbVie Inc's (NYSE: ABBV) Humira (adalimumab) to treat moderately to severely active ulcerative colitis in pediatric patients five years and older. Approved dosing for HUMIRA will be determined based on the child's weight. The approval was based on...
-
AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study
Monday, February 22, 2021 - 1:29pm | 338Read More...AbbVie Inc (NYSE: ABBV) announces data from the second Phase 3 study, U-ACCOMPLISH, evaluating upadacitinib in patients with moderate to severe ulcerative colitis. The study met the primary and secondary endpoints. 33% of patients receiving upadacitinib achieved clinical remission...
-
Here's Why Arena Pharmaceuticals Jumped 30% Today
Tuesday, March 20, 2018 - 10:24am | 381Read More...Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced an encouraging update on etrasimod, its drug candidate for the treatment of autoimmune diseases like ulcerative colitis. What Happened Arena Pharmaceuticals reported topline Phase 2 results from an ongoing trial of etrasimod called OASIS...
-
Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally
Monday, December 12, 2016 - 9:51am | 917Read More...Shares of Immune Pharmaceuticals Inc (NASDAQ: IMNP) were trending last week, gaining as much as 76 percent in three days. With no material news surfacing, it seemed like the rally was driven by a recent article that featured the company. Shares have given up most of the gains on Thursday trading....
